# Jason Ehrlich

> Jason Ehrlich is the co-founder and CEO of Ollin Biosciences, an Austin-based clinical-stage biopharma launched in September 2025 with $100 million to build best-in-disease eye medicines. An MD-PhD ophthalmologist trained at Princeton and Stanford, he spent a decade at Genentech/Roche helping shepherd retina drugs including Lucentis and the bispecific faricimab (Vabysmo), then served five years as chief medical and development officer at Kodiak Sciences. At Ollin he is taking direct aim at the market leader: in early 2026 his lead asset OLN324 beat faricimab head-to-head in a randomized Phase 1b study, drying retinas faster and deeper with a clean safety record.

- **Role:** Co-Founder & CEO at Ollin Biosciences
- **Organizations:** Ollin Biosciences, Kodiak Sciences, Genentech / Roche, Stanford University School of Medicine, Princeton University
- **Nationality:** American
- **Education:** A.B. in Molecular Biology, summa cum laude, Princeton University, M.D. and Ph.D. (NIH-funded Medical Scientist Training Program), Stanford University, Residency in Ophthalmology, Stanford University School of Medicine
- **Known for:** Co-founded and leads Ollin Biosciences, raising $100 million at launch, Lead clinician for Lucentis in diabetic eye disease, supporting the first-ever FDA approval of an intraocular drug for diabetic macular edema, Guided faricimab (later marketed as Vabysmo) into global Phase 3 development at Genentech

## Career timeline

- **2008** — Joins Genentech/Roche, working in clinical ophthalmology
- **2008-2018** — Rises to Global Head of Clinical Ophthalmology; lead clinician for Lucentis in diabetic eye disease, guides faricimab into Phase 3 and the Port Delivery System program
- **2018** — Appointed Chief Medical Officer and Chief Development Officer at Kodiak Sciences
- **2023** — Steps down from Kodiak after its lead eye therapy fails two late-stage trials; co-founds Ollin Biosciences with Atul Dandekar
- **2025** — Launches Ollin Biosciences publicly with $100M led by ARCH Venture Partners, Mubadala Capital and Monograph Capital
- **2026** — Ollin reports OLN324 beating faricimab (Vabysmo) head-to-head in the Phase 1b JADE study; plans global Phase 3

## Achievements

- Co-founded and leads Ollin Biosciences, raising $100 million at launch
- Lead clinician for Lucentis in diabetic eye disease, supporting the first-ever FDA approval of an intraocular drug for diabetic macular edema
- Guided faricimab (later marketed as Vabysmo) into global Phase 3 development at Genentech
- Reported OLN324 outperforming faricimab in a randomized head-to-head Phase 1b trial with zero cases of intraocular inflammation
- Earned A.B. summa cum laude from Princeton and MD-PhD from Stanford

## Latest updates

- **2026-02** — Full OLN324 head-to-head Phase 1b results presented at the Angiogenesis, Exudation, and Degeneration 2026 symposium on February 7, 2026.
- **2026-01** — Ollin announces positive topline data: nearly 90% of DME patients on OLN324 4mg achieved absence of disease at 12 weeks vs 57% on faricimab; plans global Phase 3 in 2026.
- **2025-09** — Ollin Biosciences launches publicly with $100M led by ARCH, Mubadala and Monograph Capital.

## Links

- Website: https://ollin.bio
- LinkedIn: http://www.linkedin.com/in/jason-ehrlich-0404364

---

Profile page: https://yespress.io/jason-ehrlich
Published by YesPress — https://yespress.io
Last updated: 2026-06-20